Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Patent
1996-12-03
1999-11-30
Housel, James C.
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
4242641, 435 26, 435 34, 435131, 435134, 435199, 536 551, 5361231, G01N 33554, C12Q 132, A61K 3902, C07H 504
Patent
active
059940905
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
The present invention relates to a novel glycoglycerophospholipid originating from Mycoplasma fermentans, an antibody against the glycoglycerophospholipid specifically existing in Mycoplasma fermentans, a method for measuring the glycoglycerophospholipid based on the use of the antibody, and a method for detecting Mycoplasma fermentans.
BACKGROUND ART
The present inventors have already found five species of glycoglycerophospholipids (phosphocholine-containing glycoglycerolipids) from MT-4 cells (human helper T cells infected with HTLV-I (human lymphotropic retrovirus Type I), Miyoshi et al., Gann., 71, 155-156 (1980)). The present inventors have been previously found that one of the five species of glycoglycerophospholipids is 6'-O-phosphocholine-.alpha.-glucopyranosyl-(1'-3)-1,2-diacyl-sn-glycerol (Shishitsu-Seikagaku-Kenkyu (Studies on Lipid Biochemistry), Vol. 35, pp. 111-114, 1993).
On the other hand, it has been reported that Mycoplasma fermentans is an exacerbation factor of human acquired immunodeficiency syndrome (AIDS) (Lo. S., -C. et al., 1991, Science, 251: 1074-1076; U.S. Pat. No. 5,242,820), or Mycoplasma fermentans is a cause of rheumatism (Williams, M. H. et al., 1970, Lancet ii: 277-280).
Various antibodies against mycoplasmas have been hitherto known, and they have been also used for clinical examination. However, the majority of them are antibodies against Mycoplasma pneumoniae or Mycoplasma genitalium. Monoclonal antibodies against these mycoplasmas have been also prepared. However, it is presumed that such an antibody is an antibody which recognizes a protein of a mycoplasma, or simultaneously recognizes a protein and a lipid of a mycoplasma.
Further, any of such antibodies does not exhibit specificity to Mycoplasma fermentans (Japanese Patent Laid-open Nos. 63-298, 63-184064, 63-32496, end 5-304990, and U.S. Pat. Nos. 5,158,1370, 4,945,041, and 5,242,820). An antibody, which exhibits specificity to Mycoplasma fermentans, is disclosed in U.S. Pat. No. 5,242,820. However, this antibody is obtained by using an entire extract of mycoplasmal cells as an immunogen, and thus the antibody is regarded as an antibody which recognizes a protein. Accordingly, if a mycoplasma contained in a body fluid such as a serum which contains various proteins is detected by using this antibody, the antibody highly possibly makes nonspecific binding. Therefore, it may be impossible to expect a high sensitivity. Further, when an antigen is a protein, it is sufficiently assumed that antigenicity disappears due to mutation in an amino acid sequence of the protein.
As far as the present inventors know, it has not been reported that any mycoplasma has a glycoglycerophospholipid containing phosphocholine. further, no instance has been known, in which a glycoglycerophospholipid originating from a mycoplasma is used as an immunogen to obtain an antibody which exhibits specificity to the glycoglycerophospholipid. Moreover, it has not been known at all as well that the antibody, which exhibits the specificity to the glycoglycerophospholipid, exhibits high specificity to Mycoplasma fermentans.
DISCLOSURE OF THE INVENTION
It has been reported that the process of pathology of a patient infected with a human immunodeficiency virus is accelerated to arrive at AIDS by infection of a mycoplasma (1991, Science, 251: 4991). It has been also reported that Mycoplasma fermentans is an exacerbation factor of AIDS as described above. However, there is no means to correctly detect such behavior of Mycoplasma fermentans in vivo. Therefore, it has been desired to provide an antibody capable of immunologically detecting Moycoplasma fermentans in vivo.
The present invention has been made considering a viewpoint as described above, an object of which is to elucidate a glycoglycerophospholipid specifically existing in Mycoplasma fermentans, and provide an antibody against the glycoglycerophospholipid, a method for measuring the glycoglycerophospholipid based on the use of the antibody, and a method for detecting Mycop
REFERENCES:
K. Matsuda et al.: "Occurence of a novel Glycolipid containing Phosphocholine in HTLV-I-infected cells", J. Glycoconjugate, vol. 10, 1993, p. 340.
H-G. Schiefer, et al.: "Localization of a phosphoglycolipid in Mycoplasma membranes using specific anti-lipid-antibodies" Zentralblatt Fur Bakteriologie,Parasitenkunde Und Hygiene, vol. 239, 1977 p.262-269.
M. Salman, et al.: "Membrane lipids of Mycoplasma fermentans", FEMS Microbiol. Lett., vol. 123, 1994, p. 255-60.
K. Matsuda, et al.: "Identification of phosphocholine-containing glycoglycerolipids purified from Mycoplasma fermentans-infected human helper T-cell culture as components of M. fermentans", Microbiol. Immunol., vol. 39, No. 5, 1995, p. 307-13.
Matsuda Kazuhiro
Yamamoto Naoki
Housel James C.
Seikagaku Corporation
Swartz Rodney P.
LandOfFree
Glycoglycerophospholipid, antibody thereagainst, and method for does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Glycoglycerophospholipid, antibody thereagainst, and method for , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glycoglycerophospholipid, antibody thereagainst, and method for will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1670321